Company news
Rakovina Therapeutics Inc news in 2026
Rakovina Therapeutics Inc's news releases, calls and decks from 2026, newest first.
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
November 16, 2026
Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov
November 12, 2026
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI(TM) Platform for DNA-Damage Response Oncology Drug Discovery
November 10, 2026
Rakovina Therapeutics Announces Shares for Debt Transaction
November 5, 2026
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
November 5, 2026
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
October 28, 2026
Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection
October 22, 2026
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
October 14, 2026
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
October 1, 2026
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
September 17, 2026
Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors
September 10, 2026
Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
August 31, 2026
Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement
August 31, 2026
Rakovina Therapeutics Announces Results from 2026 Annual General Meeting
August 19, 2026
Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
August 12, 2026
Rakovina Therapeutics Announces $1.5 Million Private Placement
July 15, 2026
Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
June 1, 2026
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
April 30, 2026
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
April 22, 2026
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum
March 23, 2026
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
March 12, 2026
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
March 5, 2026
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
February 20, 2026
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
February 4, 2026
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
January 27, 2026
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
January 8, 2026
Decks in 2026
- Investor Presentation (May 2026)
Investor deck · 28 slides · May 2026
- Investor Presentation (February 2026)
Investor deck · 25 slides · February 2026